Login to Your Account

ASCO 2011 Annual Meeting

Melanoma Trial Results Lead to 'Unprecedented' Options

By Anette Breindl

Tuesday, June 7, 2011
CHICAGO – Much-anticipated full results for two new melanoma drugs were reported at the 47th annual meeting of the American Society of Clinical Oncology (ASCO), and published online in The New England Journal of Medicine, on Sunday: the BRIM3 trial of Vemurafenib (PLX4032/RG7204, Plexxikon Inc./Roche AG) and the 024 study on Yervoy (Ipilimumab, Bristol-Myers Squibb Co.)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription